Ralf Kuriyel Net Worth

The estimated Net Worth of Ralf Kuriyel is at least $10.7 Million dollars as of 2 August 2024. Mr. Kuriyel owns over 7,148 units of Repligen stock worth over $1,762,099 and over the last 7 years he sold RGEN stock worth over $7,317,116. In addition, he makes $1,606,670 as Senior Vice President - Research and Development at Repligen.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kuriyel RGEN stock SEC Form 4 insiders trading

Ralf has made over 18 trades of the Repligen stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 7,148 units of RGEN stock worth $1,139,034 on 2 August 2024.

The largest trade he's ever made was exercising 8,000 units of Repligen stock on 10 March 2021 worth over $273,200. On average, Ralf trades about 1,658 units every 56 days since 2018. As of 2 August 2024 he still owns at least 12,288 units of Repligen stock.

You can see the complete history of Mr. Kuriyel stock trades at the bottom of the page.

Ralf Kuriyel biography

Ralf Kuriyel serves as Senior Vice President - Research and Development of the Company. Mr. Kuriyel was previously Vice President of Applications for the single-use business unit within the Life Sciences division of Pall Corporation, whose acquisition by Danaher Corporation was completed in August 2015. At Pall, Mr. Kuriyel served as Vice President of R&D, Field Applications and Process Development Services from November 2014 to October 2016. In addition, Mr. Kuriyel served as Vice President, Applications R&D at Pall from November 2011 to November 2014. Mr. Kuriyel received a B.S. and M.S. in Chemical Engineering from Rensselaer Polytechnic Institute and has completed his coursework for the Tufts University Ph.D. program in Chemical Engineering. He is an inventor of multiple patents and has co-authored over 30 scientific publications on bioprocessing, including separations technologies, membrane separations methods, protein processing and enhanced microfiltration techniques.

What is the salary of Ralf Kuriyel?

As the Senior Vice President - Research and Development of Repligen, the total compensation of Ralf Kuriyel at Repligen is $1,606,670. There are 2 executives at Repligen getting paid more, with Anthony Hunt having the highest compensation of $4,424,560.

How old is Ralf Kuriyel?

Ralf Kuriyel is 61, he's been the Senior Vice President - Research and Development of Repligen since 2016. There are 3 older and 7 younger executives at Repligen. The oldest executive at Repligen Corp. is Thomas Ryan, 78, who is the Independent Director.

What's Ralf Kuriyel's mailing address?

Ralf's mailing address filed with the SEC is C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM, MA, 02453.

Insiders trading at Repligen

Over the last 21 years, insiders at Repligen have traded over $118,224,292 worth of Repligen stock and bought 160,440 units worth $1,459,521 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Glenn P Muir, and Walter C Herlihy. On average, Repligen executives and independent directors trade stock every 33 days with the average trade being worth of $3,015,702. The most recent stock trade was executed by Ralf Kuriyel on 2 August 2024, trading 7,148 units of RGEN stock currently worth $1,139,034.

What does Repligen do?

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.

Complete history of Mr. Kuriyel stock trades at Repligen

Repligen executives and stock owners

Repligen executives and other stock owners filed with the SEC include:

• Anthony Hunt,
  President, Chief Executive Officer, Director
• Jon Snodgres,
  Chief Financial Officer
• Ralf Kuriyel,
  Senior Vice President - Research and Development
• Anthony J. Hunt,
  CEO, Pres & Director
• Jon K. Snodgres,
  Chief Financial Officer
• Ralf Kuriyel,
  Sr. VP of R&D
• Karen Dawes,
  Independent Chairperson of the Board
• Glenn Muir,
  Independent Director
• Thomas Ryan,
  Independent Director
• Nicolas Barthelemy,
  Independent Director
• Rohin Mhatre,
  Independent Director
• Carrie Eglinton,
  Director
• James Slaughter,
  Chief HR Officer
• James R. Bylund,
  Chief Operating Officer
• Christine Gebski,
  Sr. VP of Filtration & Chromatography
• Ken Elmer,
  Global Head of HR
• Rachel Goodrich,
  VP of Marketing
• Stephen Tingley,
  VP of Global Sales
• Squire Servance,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Sondra S. Newman,
  Global Head of Investor Relations
• Jim Bylund,
  Sr. VP of Operations & Information Technology
• Jason K Garland,
  CFO
• Glenn L Md Cooper,
  Director
• James R Rusche,
  Senior Vice President
• John Cox,
  Director
• Howard Benjamin,
  
• Roy T Eddleman,
  10% owner
• Christine Gebski,
  See Remarks
• G William Miller,
  Director
• Timothy Scott Harris,
  
• Barbara Burnim Day,
  Vice President
• Daniel W Muehl,
  CFO
• Partners L P/Ilbiotechnolog...,
  
• Alfred Lewis Goldberg,
  Director
• Walter C Herlihy,
  PRESIDENT, CEO
• Michael A Griffith,
  Director
• Daniel P Witt,
  Vice President
• Jonathan I Lieber,
  CFO
• Earl Webb Henry,
  Director
• William J Kelly,
  Vice President
• Alexander Rich,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Hal Landy,
  Vice President
• Paul Schimmel,
  Director
• Laura Whitehouse,
  Vice President
• Robert J Hennessey,
  Director
• Margaret Pax,
  
• Konstantin Konstantinov,
  
• Martin D Madaus,
  
• James Bylund,
  Chief Operating Officer
• Olivier Loeillot,
  Chief Executive Officer